Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 3/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28133460 | 1.00 | OAT (0.35) | OATDPP8DPP7DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL3025153 | 0.97 | OAT (0.36) | OATDPP8DPP7DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL3708706 | 0.92 | OAT (0.34) | OATDPP8DPP7DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL4543549 | 0.91 | EPHX2 (0.33) | OAT | |
| Trifluoroacetic Acid SCHEMBL4269674 | 0.91 | EPHX2 (0.33) | OAT | |
| Trifluoroacetic Acid SCHEMBL3043598 | 0.90 | MMP8 (0.33) | OATDPP8DPP7DPP4DPP9 | |
| Cycloheptanamine SCHEMBL27746259 | 0.87 | ALDH1A1 (0.36) | F2PRSS1ALDH1A1 | |
| Cyclohexylamine SCHEMBL1787821 | 0.87 | ALDH1A1 (0.36) | F2PRSS1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL2693534 | 0.87 | OAT (0.30) | OAT | |
| Trifluoroacetic Acid SCHEMBL3154223 | 0.87 | GAA (0.35) | OATL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107200749-B | DNA-PK inhibitor | 沃泰克斯药物股份有限公司 | 2019-09-03 | — | — | CN | disclosed |
| CN-107200749-A | DNA PK inhibitor | 沃泰克斯药物股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-105246883-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2017-07-21 | — | — | CN | disclosed |
| EP-2012759-B1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-03-10 | — | — | EP | disclosed |
| CN-101426482-A | Purine derivatives for use as adenosin A2A receptor agonists | NOVARTIS AG (CH) | 2009-05-06 | — | — | CN | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| EP-2012759-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1841768-B1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2007121923-A1 | PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-1841768-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074925-A1 | PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | OAT 492/4885DPP8 1429/4885DPP7 1731/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | OAT 802/4885DPP8 3517/4885DPP7 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.